Published in J Gen Intern Med on January 29, 2008
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | NCT00000542
Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med (2010) 12.04
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med (2015) 2.47
Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model. Am J Public Health (2009) 1.38
Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. Am J Hypertens (2016) 0.82
Cost implications of improving blood pressure management among U.S. adults. Health Serv Res (2011) 0.77
Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model. Hypertension (2016) 0.76
Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines. Cost Eff Resour Alloc (2012) 0.76
Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity. Medicine (Baltimore) (2015) 0.75
Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Stroke (2017) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Measurement of health state utilities for economic appraisal. J Health Econ (1986) 11.70
The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension (2004) 6.80
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
The cost-effectiveness of sildenafil. Ann Intern Med (2000) 3.62
The direct medical cost of type 2 diabetes. Diabetes Care (2003) 3.23
The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med (2001) 2.67
Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making (2001) 2.49
Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med (1997) 1.68
The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol (2002) 1.54
Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol (1996) 1.24
Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care (2001) 1.22
Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care (2003) 1.17
Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries. Ann Epidemiol (2004) 1.06
High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med (2000) 0.94
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med (2010) 12.04
The hospitalist movement 5 years later. JAMA (2002) 8.98
Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA (2002) 7.93
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med (2002) 7.00
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.54
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Adolescent overweight and future adult coronary heart disease. N Engl J Med (2007) 5.74
Implementation of a voluntary hospitalist service at a community teaching hospital: improved clinical efficiency and patient outcomes. Ann Intern Med (2002) 5.60
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
The relative safety of ephedra compared with other herbal products. Ann Intern Med (2003) 4.65
Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med (2005) 4.57
Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. JAMA (2003) 4.45
Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol (2003) 4.28
Trends in blood pressure among children and adolescents. JAMA (2004) 4.03
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol (2010) 3.85
Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol (2006) 3.85
Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med (2009) 3.83
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation (2006) 3.69
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care (2007) 3.62
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (2008) 3.56
Rapid kidney function decline and mortality risk in older adults. Arch Intern Med (2008) 3.54
Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol (2011) 3.53
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation (2006) 3.31
Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol (2005) 3.28
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2004) 3.26
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Patient quality of life during the 12 months following joint replacement surgery. Arthritis Rheum (2004) 3.16
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med (2005) 3.14
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2002) 3.05
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol (2011) 2.90
Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension (2003) 2.87
The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med (2004) 2.86
Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation (2008) 2.85
Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol (2003) 2.83
Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med (2009) 2.81
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA (2002) 2.73
Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med (2015) 2.72
Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med (2007) 2.71
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation (2011) 2.64
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes (2010) 2.63
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2006) 2.61
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol (2011) 2.56
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol (2005) 2.52
Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation (2006) 2.50
Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med (2015) 2.47
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 2.41
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 2.41
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40